Wang B S, Steele G, Onikul S R, Mannick J A
Ann N Y Acad Sci. 1979;332:207-15. doi: 10.1111/j.1749-6632.1979.tb47114.x.
The effect of I-RNA therapy was studied in a B16 melanoma-C57BL/6J mouse system. After having primary B16 isografts excised, mice receiving syngeneic lymphocytes incubated in vitro with specific guinea pig B16 I-RNA showed significantly improved survival as compared to control mice receiving untreated lymphocytes. This therapeutic effect was tumor specific and RNase sensitive. Significant cytotoxicity against B16 cells in vitro was consistently observed with lymphocytes prepared from B16 I-RNA treated animals, whereas lymphocytes from control animals or those treated with RNase-degraded B16 I-RNA or 3LL I-RNA had no effect. Results suggest that the combination of surgery and immunotherapy with I-RNA may be useful in preventing tumor recurrence in certain patients with cancer.
在B16黑色素瘤-C57BL/6J小鼠系统中研究了免疫核糖核酸（I-RNA）疗法的效果。在切除原发性B16同基因移植瘤后，与接受未处理淋巴细胞的对照小鼠相比，接受与特异性豚鼠B16 I-RNA体外孵育的同基因淋巴细胞的小鼠存活率显著提高。这种治疗效果具有肿瘤特异性且对核糖核酸酶敏感。用来自B16 I-RNA处理动物制备的淋巴细胞在体外始终观察到对B16细胞有显著的细胞毒性，而来自对照动物或用核糖核酸酶降解的B16 I-RNA或3LL I-RNA处理的淋巴细胞则没有作用。结果表明，手术与I-RNA免疫疗法相结合可能有助于预防某些癌症患者的肿瘤复发。
